Clinical Trials
10 trialsNCT04994132 2026-05-05
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT07466316 2026-03-12
A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Children's Oncology Group
Phase 3 Not yet recruiting
NCT00354835 2023-01-31
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Completed
NCT00075582 2021-11-19
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Completed
NCT00354744 2020-01-29
High-Dose Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Metastatic Rhabdomyosarcoma or Ectomesenchymoma
Children's Oncology Group
Phase 3 Completed
NCT00061984 2014-10-27
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00002641 2014-08-08
Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00002995 2014-02-14
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Completed
NCT00003958 2013-06-17
Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma
Children's Oncology Group
Phase 3 Completed
NCT00003212 2012-01-20
Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed